The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
Sign Up to like & getrecommendations! Published in 2018 at "Blood Cancer Journal"
DOI: 10.1038/s41408-018-0078-3
Abstract: Once-daily (od), low-dose aspirin (75–100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia… read more here.
Keywords: aspirin regimens; trial; serum; aspirin ... See more keywords